Thursday’s General Session included data from trials looking at the efficacy of the next-generation SERD camizestrant, the investigational AKT inhibitor capivasertib, and the use of circulating tumor cell count to guide the choice between chemotherapy and endocrine therapy.
During a Thursday debate session, Ruth O’Regan, MD, and Debra Patt, MD, PhD, MBA, argued whether the impacts of CDK4/6 inhibitors had more to do with patient selection or molecular structure and potency of agents.
Geoffrey M. Wahl, PhD, received the Brinker Award for Scientific Distinction in Basic Science on Thursday and emphasized the necessity of interdisciplinary alliances and mentorship to further scientific research.
Norman Wolmark, MD, FACS, FRCSC, will receive the Brinker Award for Scientific Distinction in Clinical Research on Friday, and will deliver the lecture “The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer: PAST AS PROLOGUE.”
Wednesday’s General Session included data from three trials looking at the use of the antibody drug conjugate trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic and HER-2-low, HR-positive early-stage breast cancer.